RESUMEN
In patients receiving prophylactic lamivudine (LAM) and chemotherapy, hepatitis B virus (HBV) reactivation cannot be eliminated without knowing the latent causes and optimal management. In our previous study, virus breakthrough and relapse were highly suspected as potential virologic causes for HBV reactivation. Therefore, we reviewed 24 previous studies and 447 patients who underwent chemotherapy and prophylactic LAM, with an incidence of 7.2 % HBV reactivation. Virus breakthrough and relapse were seldom investigated in these studies. In addition, 72 patients that underwent prophylactic LAM and chemotherapy at our centers were also analyzed. Among them, eight patients developed virus breakthrough, with another nine developing virus relapse after discontinuation of LAM. Eight patients received antiviral modification, which included administration of adefovir for patients with virus breakthrough or resumption of LAM for patients with virus relapse and none of them developed HBV reactivation. In contrast, of the nine patients who did not receive antiviral modification, six developed HBV reactivation and two died. In conclusion, this study demonstrated that virus breakthrough and relapse were the critical causative factors of HBV reactivation in patients receiving chemotherapy and prophylactic LAM. An optimized antiviral modification strategy could effectively prevent HBV reactivation in patients with virus breakthrough or relapse.
Asunto(s)
Antineoplásicos/uso terapéutico , Antivirales/uso terapéutico , Hepatitis B/prevención & control , Lamivudine/uso terapéutico , Neoplasias/tratamiento farmacológico , Prevención Secundaria , Activación Viral/efectos de los fármacos , Adolescente , Adulto , Anciano , Femenino , Antígenos de la Hepatitis/metabolismo , Hepatitis B/etiología , Hepatitis B/mortalidad , Virus de la Hepatitis B/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/complicaciones , Neoplasias/virología , Proyectos Piloto , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Tasa de Supervivencia , Resultado del Tratamiento , Adulto JovenRESUMEN
Hepatitis C virus (HCV) infection causes significant morbidity and mortality worldwide. T cells play a central role in HCV clearance; however, there is currently little understanding of whether the disease outcome in HCV infection is influenced by the choice of TCR repertoire. TCR repertoires used against two immunodominant HCV determinants--the highly polymorphic, HLA-B*0801 restricted (1395)HSKKKCDEL(1403) (HSK) and the comparatively conserved, HLA-A*0101-restricted, (1435)ATDALMTGY(1443) (ATD)--were analyzed in clearly defined cohorts of HLA-matched, HCV-infected individuals with persistent infection and HCV clearance. In comparison with ATD, TCR repertoire selected against HSK was more narrowly focused, supporting reports of mutational escape in this epitope, in persistent HCV infection. Notwithstanding the Ag-driven divergence, T cell repertoire selection against either Ag was comparable in subjects with diverse disease outcomes. Biased T cell repertoires were observed early in infection and were evident not only in persistently infected individuals but also in subjects with HCV clearance, suggesting that these are not exclusively characteristic of viral persistence. Comprehensive clonal analysis of Ag-specific T cells revealed widespread use of public TCRs displaying a high degree of predictability in TRBV/TRBJ gene usage, CDR3 length, and amino acid composition. These public TCRs were observed against both ATD and HSK and were shared across diverse disease outcomes. Collectively, these observations indicate that repertoire diversity rather than particular Vß segments are better associated with HCV persistence/clearance in humans. Notably, many of the anti-HCV TCRs switched TRBV and TRBJ genes around a conserved, N nucleotide-encoded CDR3 core, revealing TCR sequence mosaicism as a potential host mechanism to combat this highly variant virus.
Asunto(s)
Hepacivirus/inmunología , Antígenos de la Hepatitis/biosíntesis , Hepatitis C Crónica/inmunología , Receptores de Antígenos de Linfocitos T/metabolismo , Secuencia de Aminoácidos , Secuencia de Bases , Epítopos de Linfocito T/biosíntesis , Variación Genética/inmunología , Antígenos HLA-A/genética , Antígenos HLA-B/genética , Antígenos de la Hepatitis/metabolismo , Antígenos de la Hepatitis/fisiología , Hepatitis C Crónica/metabolismo , Humanos , Evasión Inmune , Epítopos Inmunodominantes/inmunología , Datos de Secuencia MolecularRESUMEN
Transcription elongation by RNA polymerase II (RNAPII) is negatively regulated by the human factors DRB-sensitivity inducing factor (DSIF) and negative elongation factor (NELF). A 66-kilodalton subunit of NELF (NELF-A) shows limited sequence similarity to hepatitis delta antigen (HDAg), the viral protein required for replication of hepatitis delta virus (HDV). The host RNAPII has been implicated in HDV replication, but the detailed mechanism and the role of HDAg in this process are not understood. We show that HDAg binds RNAPII directly and stimulates transcription by displacing NELF and promoting RNAPII elongation. These results suggest that HDAg may regulate RNAPII elongation during both cellular messenger RNA synthesis and HDV RNA replication.
Asunto(s)
Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta , ARN Polimerasa II/metabolismo , Transcripción Genética , Secuencia de Aminoácidos , Secuencia de Bases , Secuencia de Consenso/genética , Activación Enzimática , Células HeLa , Antígenos de la Hepatitis/química , Virus de la Hepatitis Delta/química , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/metabolismo , Antígenos de Hepatitis delta , Humanos , Datos de Secuencia Molecular , Unión Proteica , Subunidades de Proteína , ARN Viral/biosíntesis , ARN Viral/genética , Alineación de Secuencia , Moldes Genéticos , Factores de Transcripción/antagonistas & inhibidores , Factores de Transcripción/química , Factores de Transcripción/metabolismo , Replicación ViralRESUMEN
Hepatitis delta virus (HDV) is a pathogenic human virus whose RNA genome and replication cycle resemble those of plant viroids. However, viroid genomes contain no open reading frames, whereas HDV RNA encodes a single protein, hepatitis delta antigen (HDAg), which is required for viral replication. A cellular gene whose product interacts with HDAg has now been identified, and this interaction was found to affect viral genomic replication in intact cells. DNA sequence analysis revealed that this protein, termed delta-interacting protein A (DIPA), is a cellular homolog of HDAg. These observations demonstrate that a host gene product can modulate HDV replication and suggest that HDV may have evolved from a primitive viroidlike RNA through capture of a cellular transcript.
Asunto(s)
Evolución Biológica , Proteínas Portadoras/química , Antígenos de la Hepatitis/química , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/genética , Proteínas Adaptadoras Transductoras de Señales , Secuencia de Aminoácidos , Proteínas Portadoras/genética , Proteínas Portadoras/metabolismo , Línea Celular , Clonación Molecular , Genoma Viral , Antígenos de la Hepatitis/genética , Virus de la Hepatitis Delta/fisiología , Antígenos de Hepatitis delta , Humanos , Hígado/química , Datos de Secuencia Molecular , ARN Mensajero/genética , ARN Viral/genética , Proteínas Represoras , Alineación de Secuencia , Transfección , Células Tumorales Cultivadas , Viroides/genética , Replicación ViralRESUMEN
Nitazoxanide (NTZ), a thiazolide anti-infective, is active against anaerobic bacteria, protozoa, and a range of viruses in cell culture models, and is currently in phase II clinical development for treating chronic hepatitis C. In this report, we characterize the activities of NTZ and its active metabolite, tizoxanide (TIZ), along with other thiazolides against hepatitis B virus (HBV) and hepatitis C virus (HCV) replication in standard antiviral assays. NTZ and TIZ exhibited potent inhibition of both HBV and HCV replication. NTZ was equally effective at inhibiting replication of lamivudine (LMV) and adefovir dipovoxil (ADV)-resistant HBV mutants and against 2'-C-methyl cytidine (2'CmeC) and telaprevir (VX-950)-resistant HCV mutants. NTZ displayed synergistic interactions with LMV or ADV against HBV, and with recombinant interferon alpha-2b (IFN) or 2'CmeC against HCV. Pre-treatment of HCV replicon-containing cells with NTZ potentiated the effect of subsequent treatment with NTZ plus IFN, but not NTZ plus 2'CmeC. NTZ induced reductions in several HBV proteins (HBsAg, HBeAg, HBcAg) produced by 2.2.15 cells, but did not affect HBV RNA transcription. NTZ, TIZ, and other thiazolides are promising new antiviral agents that may enhance current or future anti-hepatitis therapies.
Asunto(s)
Antivirales/farmacología , Hepacivirus/efectos de los fármacos , Virus de la Hepatitis B/efectos de los fármacos , Tiazoles/farmacología , Replicación Viral/efectos de los fármacos , Antivirales/metabolismo , Línea Celular , Farmacorresistencia Viral , Hepacivirus/genética , Hepacivirus/fisiología , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/fisiología , Humanos , Mutación , Nitrocompuestos , Suero , Tiazoles/metabolismoRESUMEN
RNA editing at adenosine 1012 (amber/W site) in the antigenomic RNA of hepatitis delta virus (HDV) allows two essential forms of the viral protein, hepatitis delta antigen (HDAg), to be synthesized from a single open reading frame. Editing at the amber/W site is thought to be catalyzed by one of the cellular enzymes known as adenosine deaminases that act on RNA (ADARs). In vitro, the enzymes ADAR1 and ADAR2 deaminate adenosines within many different sequences of base-paired RNA. Since promiscuous deamination could compromise the viability of HDV, we wondered if additional deamination events occurred within the highly base paired HDV RNA. By sequencing cDNAs derived from HDV RNA from transfected Huh-7 cells, we determined that the RNA was not extensively modified at other adenosines. Approximately 0.16 to 0.32 adenosines were modified per antigenome during 6 to 13 days posttransfection. Interestingly, all observed non-amber/W adenosine modifications, which occurred mostly at positions that are highly conserved among naturally occurring HDV isolates, were found in RNAs that were also modified at the amber/W site. Such coordinate modification likely limits potential deleterious effects of promiscuous editing. Neither viral replication nor HDAg was required for the highly specific editing observed in cells. However, HDAg was found to suppress editing at the amber/W site when expressed at levels similar to those found during HDV replication. These data suggest HDAg may regulate amber/W site editing during virus replication.
Asunto(s)
Regulación Viral de la Expresión Génica , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/genética , Edición de ARN , ARN Viral/metabolismo , Secuencia de Bases , Virus de la Hepatitis Delta/fisiología , Antígenos de Hepatitis delta , Humanos , Datos de Secuencia Molecular , Conformación de Ácido Nucleico , Relación Estructura-Actividad , Transfección , Células Tumorales Cultivadas , Replicación ViralRESUMEN
BACKGROUND: The hepatitis D virus (HDV) is a small satellite virus of hepatitis B virus (HBV). Coinfection with HBV and HDV causes severe liver disease in humans. The small 195 amino-acid form of the hepatitis delta antigen (HDAg) functions as a trans activator of HDV replication. A larger form of the protein containing a 19 amino acid C-terminal extension inhibits viral replication. Both of these functions are mediated in part by a stretch of amino acids predicted to form a coiled coil (residues 13-48) that is common to both forms. It is believed that HDAg forms dimers and higher ordered structures through this coiled-coil region. RESULTS: The high-resolution crystal structure of a synthetic peptide corresponding to residues 12 to 60 of HDAg has been solved. The peptide forms an antiparallel coiled coil, with hydrophobic residues near the termini of each peptide forming an extensive hydrophobic core with residues C-terminal to the coiled-coil domain in the dimer protein. The structure shows how HDAg forms dimers, but also shows the dimers forming an octamer that forms a 50 A ring lined with basic sidechains. This is confirmed by cross-linking studies of full-length recombinant small HDAg. CONCLUSIONS: HDAg dimerizes through an antiparallel coiled coil. Dimers then associate further to form octamers through residues in the coiled-coil domain and residues C-terminal to this region. Our findings suggest that the structure of HDAg represents a previously unseen organization of a nucleocapsid protein and raise the possibility that the N terminus may play a role in binding the viral RNA.
Asunto(s)
Antígenos de la Hepatitis/química , Secuencia de Aminoácidos , Cristalografía por Rayos X , Antígenos de la Hepatitis/metabolismo , Antígenos de Hepatitis delta , Espectrometría de Masas , Modelos Moleculares , Datos de Secuencia Molecular , Fragmentos de Péptidos/química , Fragmentos de Péptidos/metabolismo , Prolina , Conformación Proteica , Homología de Secuencia de AminoácidoRESUMEN
Hepatitis delta antigen (HDAg) is the only viral-encoded protein of the hepatitis delta virus (HDV). This protein has been extensively characterized with respect to its biochemical and functional properties. However, the molecular mechanism responsible for persistent HDV infection is not yet clear. Previously, we reported that overexpression of HDAg protects insect cells from baculovirus-induced cytolysis [Hwang, S.B. Park, K.-J. and Kim, Y.S. (1998) Biochem. Biophys. Res. Commun. 244, 652-658]. Here we report that HDAg mediates cell cycle arrest when overexpressed in recombinant baculovirus-infected insect cells. Flow cytometry analysis has shown that HDAg expression in Spodoptera frugiperda cells causes an accumulation of substantial amounts of polyploid DNA in the absence of cell division. This phenomenon may be partly responsible for the persistent infection of chronic HDV patients.
Asunto(s)
Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/metabolismo , Animales , Ciclo Celular , División Celular , Línea Celular , Supervivencia Celular , ADN/análisis , Antígenos de la Hepatitis/genética , Antígenos de Hepatitis delta , Poliploidía , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Spodoptera/citología , Proteínas no Estructurales Virales/genética , Proteínas no Estructurales Virales/metabolismoAsunto(s)
Proteínas Portadoras/genética , Virus de la Hepatitis Delta/genética , ARN Mensajero/genética , ARN Viral/biosíntesis , ARN Viral/genética , Proteínas Adaptadoras Transductoras de Señales , Proteínas Portadoras/química , Proteínas Portadoras/metabolismo , Genes , Antígenos de la Hepatitis/genética , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/fisiología , Antígenos de Hepatitis delta , Humanos , Intrones , Hígado/química , Proteínas Represoras , Viroides/genética , Replicación ViralRESUMEN
Replication of hepatitis delta virus (HDV) is dependent on delta antigen (deltaAg), an HDV-encoded protein, which binds to HDV RNA and is capable of multimerization. To characterize HDV-specific ribonucleoprotein complexes (RNP) we used electrophoresis into non-denaturing agarose gels followed by northern analysis, to detect HDV RNA, and immunoblot, to detect deltaAg. We studied RNP from three sources: (i) vRNP, disrupted virions obtained from infected woodchuck serum; (ii) sRNP, disrupted particles secreted from transfected cultured cells; and (iii) cRNP, isolated from cells in which HDV genome replication was occurring. sRNP were approximately 28% smaller than vRNP. Treatment of vRNP with aurin tricarboxylic acid disrupted both deltaAg-deltaAg and deltaAg-RNA interactions while vanadyl ribonucleosides released the RNA without causing detectable disruption of the multimeric deltaAg complex. cRNP were smaller and more heterogeneous than vRNP and sRNP, and probably contained host components. The application of these electrophoretic procedures, and especially the use of prior treatments with vanadyl ribonucleoside complexes have provided valuable information on the RNP of HDV, and we expect they should find applicability in RNP studies of other RNA viruses.
Asunto(s)
Electroforesis en Gel de Agar/métodos , Antígenos de la Hepatitis/análisis , Virus de la Hepatitis Delta/inmunología , Ribonucleoproteínas/análisis , Animales , Ácido Aurintricarboxílico/farmacología , Northern Blotting , Línea Celular/virología , Antígenos de la Hepatitis/efectos de los fármacos , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/genética , Antígenos de Hepatitis delta , Humanos , Immunoblotting , Marmota/sangre , Marmota/virología , Unión Proteica , Ribonucleoproteínas/efectos de los fármacos , Ribonucleoproteínas/metabolismo , Ribonucleósidos/farmacologíaRESUMEN
A new method is described for the characterization of RNA binding domains of a protein and applied to the study of the interaction between proteins and nucleic acid of the human hepatitis delta virus (HDV). The method uses synthetic peptides coated onto an ELISA plate and tested for their ability to bind digoxigenin-labelled RNAs. RNA binding is quantified with peroxidase-conjugated anti-digoxigenin. The hepatitis delta antigen (HDAg) is an RNA-binding protein that specifically binds HDV RNAs. In a previous study, it was shown that HDAg sequences corresponding to residues 2-27 and 79-107 bound to both genomic and antigenomic strands. Further investigations are reported on HDAg/HDV RNA binding, using additional HDAg peptides and the full-length HDV genomic and antigenomic strands. In order to validate the method, the efficiency of peptide coating onto the ELISA plate was assessed with human antibodies against HDAg. The two arginine-rich motifs potentially involved in the RNA-binding activity (97-107 and 136-146) were explored and the residues 2-27 and 79-211 were mapped using synthetic peptides. Only peptides corresponding to residues 2-17, 2-27, 79-107 and 84-126 of the HDAg bound to the genomic and antigenomic strands. The second arginine-rich motif represented by peptides 130-144 and 128-152 did not bind to HDV RNAs in this assay. This second arginine-rich domain may be involved in this interaction without a direct ability to bind HDV RNAs.
Asunto(s)
Ensayo de Inmunoadsorción Enzimática/métodos , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/metabolismo , ARN Viral/metabolismo , Proteínas de Unión al ARN/metabolismo , Secuencia de Aminoácidos , Arginina/metabolismo , Sitios de Unión , Digoxigenina/química , Antígenos de la Hepatitis/química , Antígenos de la Hepatitis/inmunología , Virus de la Hepatitis Delta/química , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/inmunología , Antígenos de Hepatitis delta , Humanos , Datos de Secuencia Molecular , Mapeo Peptídico , Péptidos/síntesis química , Péptidos/inmunología , Péptidos/metabolismo , Unión Proteica , Proteínas de Unión al ARN/químicaRESUMEN
Synthetic antisense oligodeoxynucleotides (ODNs) and a system containing transcription and translation coupled rabbit reticulocyte lysate were used to develop a new model modulating the synthesis of small delta antigen which, in turn, inhibits the replication of HDV (hepatitis D virus). The ODN was stable for at least 50 min in this system at 37 degrees C. Unmodified 15-mer antisense D3 and D4, complementary to translation initiation region and coding region, respectively, inhibit the synthesis of small delta antigen by 95% at a concentration of 5 microM, whereas antisenses complementary to 5' noncoding region, stop codon region and polyadenylation site were less effective. This system also showed a dose-dependent inhibitory effect of antisense D3 on the production of the target protein. However, the synthesis of E6 protein, an internal control, was not affected. These observations imply that this in vitro system is convenient for rapid screening of effective antisense compounds and offers a promising perspective for the investigation of translation mechanisms and for the inhibition of HDV replication by antisense strategy.
Asunto(s)
Antígenos de la Hepatitis/efectos de los fármacos , Antígenos de la Hepatitis/metabolismo , Oligonucleótidos Antisentido/farmacología , Biosíntesis de Proteínas/efectos de los fármacos , Animales , Sistema Libre de Células , Virus Defectuosos , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Virus de la Hepatitis Delta/efectos de los fármacos , Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/metabolismo , Antígenos de Hepatitis delta , Oligonucleótidos Antisentido/metabolismo , Proteínas de Unión al ARN/antagonistas & inhibidores , Proteínas de Unión al ARN/metabolismo , Conejos , Reticulocitos/química , Reticulocitos/metabolismo , Transcripción Genética/efectos de los fármacosRESUMEN
Alcohol drinking and viral hepatitis are both recognized as major causes of liver disease worldwide, and they frequently coexist and synergistically cause liver injury in patients with chronic liver disease. Several mechanisms have been implicated in exacerbation of liver injury in patients with alcohol drinking and viral hepatitis. These include impairment of host defense and liver regeneration by alcohol consumption. The findings obtained from my laboratory have demonstrated that alcohol potentiates cooperatively several signals activated by hepatitis B virus X protein (HBX) or hepatitis C virus core protein, and HBX sensitizes hepatocytes to tumor necrosis factor-alpha (TNF-alpha)- and ethanol-induced apoptosis by a caspase-3-dependent mechanism, which may also contribute to the synergistic effect of alcohol drinking and viral hepatitis on liver injury.
Asunto(s)
Consumo de Bebidas Alcohólicas/metabolismo , Antígenos de la Hepatitis/metabolismo , Hepatitis Alcohólica/metabolismo , Hepatitis Alcohólica/virología , Hígado/metabolismo , Animales , Etanol/efectos adversos , Etanol/metabolismo , Hepatitis B/inducido químicamente , Hepatitis B/metabolismo , Hepatitis C/inducido químicamente , Hepatitis C/metabolismo , Humanos , Hígado/patología , Hígado/virologíaRESUMEN
Short-term antiviral therapy with the nucleoside analogue entecavir (ETV), given at an early stage of duck hepatitis B virus (DHBV) infection, restricts virus spread and leads to clearance of DHBV-infected hepatocytes in approximately 50% of ETV-treated ducks, whereas widespread and persistent DHBV infection develops in 100% of untreated ducks. To increase the treatment response rate, ETV treatment was combined in the current study with a post-exposure "prime-boost" vaccination protocol. Four groups of 14-day-old ducks were inoculated intravenously with a dose of DHBV previously shown to induce persistent DHBV infection. One hour post-infection (p.i.), ducks were primed with DNA vaccines that expressed DHBV core (DHBc) and surface (pre-S/S and S) antigens (Groups A, B) or the DNA vector alone (Groups C, D). ETV (Groups A, C) or water (Groups B, D) was simultaneously administered by gavage and continued for 14 days. Ducks were boosted 7 days p.i. with recombinant fowlpoxvirus (rFPV) strains also expressing DHBc and pre-S/S antigens (Groups A, B) or the FPV-M3 vector (Groups C, D). DHBV-infected hepatocytes were observed in the liver of all ducks at day 4 p.i. with reduced numbers in the ETV-treated ducks. Ducks treated with ETV plus the control vectors showed restricted spread of DHBV infection during ETV treatment, but in 60% of cases, infection became widespread after ETV was stopped. In contrast, at 14 and 67 days p.i., 100% of ducks treated with ETV and "prime-boost" vaccination had no detectable DHBV-infected hepatocytes and had cleared the DHBV infection. These findings suggest that ETV treatment combined with post-exposure "prime-boost" vaccination induced immune responses that eliminated DHBV-infected hepatocytes and prevented the development of persistent DHBV infection.
Asunto(s)
Antivirales/administración & dosificación , Patos/virología , Guanina/análogos & derivados , Infecciones por Hepadnaviridae/veterinaria , Virus de la Hepatitis B del Pato/efectos de los fármacos , Virus de la Hepatitis B del Pato/patogenicidad , Hepatitis Viral Animal/prevención & control , Vacunas contra Hepatitis Viral/administración & dosificación , Animales , Secuencia de Bases , Cartilla de ADN/genética , Virus de la Viruela de las Aves de Corral/genética , Guanina/administración & dosificación , Infecciones por Hepadnaviridae/tratamiento farmacológico , Infecciones por Hepadnaviridae/inmunología , Infecciones por Hepadnaviridae/prevención & control , Antígenos de la Hepatitis/genética , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis B del Pato/inmunología , Hepatitis Viral Animal/tratamiento farmacológico , Hepatitis Viral Animal/inmunología , Hepatocitos/efectos de los fármacos , Hepatocitos/virología , Inmunización Secundaria , Plásmidos/genética , Vacunas de ADN/administración & dosificación , Vacunas de ADN/genética , Vacunas contra Hepatitis Viral/genéticaRESUMEN
The large form of the hepatitis delta virus (HDV) protein (L) can be isoprenylated near its C terminus, and this modification is considered essential for particle assembly. Using gel electrophoresis, we separated L into two species of similar mobilities. The slower species could be labeled by the incorporation of [(14)C]mevalonolactone and is interpreted to be isoprenylated L (L(i)). In serum particles, infected liver, transfected cells, and assembled particles, 25 to 85% of L was isoprenylated. Isoprenylation was also demonstrated by (14)C incorporation in vitro with a rabbit reticulocyte coupled transcription-translation system. However, the species obtained migrated even slower than that detected by labeling in vivo. Next, in studies of HDV particle assembly in the presence of the surface proteins of human hepatitis B virus, we observed the following. (i) Relative to L, L(i) was preferentially assembled into virus-like particles. (ii) L(i) could coassemble the unmodified L and the small delta protein, S. (iii) In contrast, a form of L with a deletion in the dimerization domain was both isoprenylated and assembled, but it could not support the coassembly of S. Finally, to test the expectation that the isoprenylation of L would increase its hydrophobicity, we applied a phase separation strategy based on micelle formation with the nonionic detergent Triton X-114. We showed the following. (i) The unique C-terminal 19 amino acids present on L relative to S caused a significant increase in the hydrophobicity. (ii) This increase was independent of isoprenylation. (iii) In contrast, other, artificial modifications at either the N or C terminus of S did not increase the hydrophobicity. (iv) The increased hydrophobicity was not sufficient for particle assembly; nevertheless, we speculate that it might facilitate virion assembly.
Asunto(s)
Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/metabolismo , Secuencia de Aminoácidos , Animales , Electroforesis en Gel de Poliacrilamida , Antígenos de Hepatitis delta , Humanos , Datos de Secuencia Molecular , Conejos , Reticulocitos , Homología de Secuencia de Aminoácido , Células Tumorales CultivadasRESUMEN
Hepatitis delta virus (HDV) replication requires both the cellular RNA polymerase and one virus-encoded protein, small delta antigen (S-HDAg). S-HDAg has been shown to be a phosphoprotein, but its phosphorylation status is not yet clear. In this study, we employed three methods to address this question. A special two-dimensional gel electrophoresis, namely, nonequilibrium pH gradient electrophoresis, was used to separate the very basic S-HDAg. By carefully adjusting the pH of solubilization solution, the ampholyte composition, and the appropriate electrophoresis time periods, we were able to clearly resolve S-HDAg into two phosphorylated isoforms and one unphosphorylated form. In contrast, the viral large delta antigen (L-HDAg) can only be separated into one phosphorylated and one unphosphorylated form. By metabolic (32)P labeling, both immunoprecipitated S-HDAg and L-HDAg were found to incorporate radioactive phosphate. The extent of S-HDAg phosphorylation was increased upon 12-O-tetradecanoylphorbol-13-acetate treatment, while that of L-HDAg was not affected. Finally, phosphoamino acid analysis identified serine and threonine as the phospho residues in the labeled S-HDAg and only serine in the L-HDAg. Therefore, HDV S- and L-HDAgs differ in their phosphorylation patterns, which may account for their distinct biological functions.
Asunto(s)
Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta , Secuencia de Aminoácidos , Electroforesis en Gel Bidimensional , Antígenos de Hepatitis delta , Humanos , Punto Isoeléctrico , Datos de Secuencia Molecular , Fosforilación , Isoformas de Proteínas , Serina/metabolismo , Treonina/metabolismo , Células Tumorales CultivadasRESUMEN
The large delta antigen (LDAg) of hepatitis D virus (HDV), which is similar to the small delta antigen (SDAg), except it has 19 additional amino acids and an isoprenylation signal at the C-terminus, is crucial for interacting with hepatitis B surface antigen (HBsAg) to form a mature virion of HDV. Previous studies indicated that the LDAg alone, but not SDAg, can interact with HBsAg to form an empty particle. However, no evidence yet shows whether the intermolecular interaction of LDAg is necessary for forming an empty HDV particle. By cotransfection of plasmids encoding deletion or isoprenylation-negative mutants of LDAg with a plasmid encoding HBsAg into human hepatoma cells, we demonstrated that (i) the isoprenylation-negative LDAg cannot be secreted, (ii) the coiled-coil domain-deleted LDAg retains the secretion capability, (iii) the isoprenylation-negative LDAg can neither cosecrete with isoprenylation-positive LDAg nor suppress its secretion, and (iv) an intermolecular interaction between LDAgs is unlikely required for secretion. A hypothetical model of empty HDV particle containing HBsAg with isoprenylated LDAgs, which are probably present in a singular form, was then proposed.
Asunto(s)
Antígenos de la Hepatitis/metabolismo , Antígenos de Superficie de la Hepatitis B/metabolismo , Virus de la Hepatitis Delta/fisiología , Virus de la Hepatitis Delta/metabolismo , Antígenos de Hepatitis delta , Humanos , Modelos Biológicos , Eliminación de Secuencia , Células Tumorales Cultivadas , Ensamble de VirusRESUMEN
The hepatitis delta virus (HDV) nucleocapsid consists of a genomic-length RNA of 1.7 kb and approximately equimolar amounts of the small and large forms of the hepatitis delta antigen (S-HDAg and L-HDAg, respectively). Since HDV RNA particles contain not only a genomic RNA species encoding S-HDAg but also an RNA species encoding L-HDAg, which is produced by an RNA-editing process, the question arises as to whether RNAs encoding either L-HDAg or S-HDAg can initiate replication. To study this, two cDNA-free transfection methods were employed: HDV RNA cotransfected with either the S-HDAg-encoding mRNA species or the ribonucleocapsid protein complex, comprising HDV RNA and recombinant S-HDAg. Results showed that the genomic-sense RNA encoding S-HDAg could promote HDV replication, whereas the L-HDAg-encoding RNA species was unable to replicate under the same conditions. The antigenomic RNA species encoding either S-HDAg or L-HDAg could not replicate by either of these procedures. In addition, L-HDAg alone could not promote replication of the genomic RNA but, by supplementing an equal amount of S-HDAg, replication occurred. These data indicate that L-HDAg-encoding RNA species are probably not involved in the initiation of HDV RNA synthesis; instead, their main function may be to serve as template for producing L-HDAg, which regulates HDV RNA synthesis and virion assembly. These results suggest that the genomic RNA species encoding S-HDAg is the only functional genome for HDV infection and explain why the presence of the edited HDV RNA encoding L-HDAg does not interfere with HDV infection.
Asunto(s)
Antígenos de la Hepatitis/genética , Virus de la Hepatitis Delta/genética , ARN Viral/biosíntesis , Proteínas de Unión al ARN/genética , Replicación Viral/fisiología , Animales , Células COS , Chlorocebus aethiops , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/fisiología , Antígenos de Hepatitis delta , Mutagénesis Sitio-Dirigida , Proteínas de Unión al ARN/metabolismo , Moldes Genéticos , TransfecciónRESUMEN
RNA editing at the amber/W site plays a central role in the replication scheme of hepatitis delta virus (HDV), allowing the virus to produce two functionally distinct forms of the sole viral protein, hepatitis delta antigen (HDAg), from the same open reading frame. Editing is carried out by a cellular activity known as ADAR (adenosine deaminase), which acts on RNA substrates that are at least partially double stranded. In HDV genotype I, editing requires a highly conserved base-paired structure that occurs within the context of the unbranched rod structure characteristic of HDV RNA. This base-paired structure is disrupted in the unbranched rod of HDV genotype III, which is the most distantly related of the three known HDV genotypes and is associated with the most severe disease. Here I show that RNA editing in HDV genotype III requires a branched double-hairpin structure that deviates substantially from the unbranched rod structure, involving the rearrangement of nearly 80 bp. The structure includes a UNCG RNA tetraloop, a highly stable structural motif frequently involved in the folding of large RNAs such as rRNA. The double-hairpin structure is required for editing, and hence for virion formation, but not for HDV RNA replication, which requires the unbranched rod structure. HDV genotype III thus relies on a dynamic conformational switch between the two different RNA structures: the unbranched rod characteristic of HDV RNA and a branched double-hairpin structure that is required for RNA editing. The different mechanisms of editing in genotypes I and III underscore their functional differences and may be related to pathogenic differences as well.
Asunto(s)
Virus de la Hepatitis Delta/genética , Virus de la Hepatitis Delta/metabolismo , Edición de ARN , ARN Viral/química , ARN Viral/metabolismo , Secuencia de Bases , Genotipo , Antígenos de la Hepatitis/metabolismo , Virus de la Hepatitis Delta/clasificación , Antígenos de Hepatitis delta , Humanos , Datos de Secuencia Molecular , Mutación , Conformación de Ácido Nucleico , ARN Viral/genética , Análisis de Secuencia de ADN , Relación Estructura-Actividad , Transfección , Células Tumorales Cultivadas , Virión/metabolismo , Replicación ViralRESUMEN
We used two-dimensional electrophoresis (nonequilibrium pH gradient electrophoresis followed by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis) coupled with 32P labeling and immunoblotting detection with 125I-protein A to detect and quantitate phosphorylation of the large and small forms of the delta antigen (deltaAg-L and deltaAg-S, respectively). Analysis of deltaAg species from the serum and liver of an infected woodchuck as well as deltaAg species expressed in and secreted from transfected Huh7 cells revealed the following. (i) No detectable phosphorylation of deltaAg-S occurred. (ii) In virions from the serum of an infected animal and in the particles secreted from cotransfected cells, none of the deltaAg-L was phosphorylated. (iii) Only in the infected liver and in transfected cells was any phosphorylation detected; it corresponded to a monophosphorylated form of deltaAg-L. Given these results, we carried out serine-to-alanine mutagenesis of the deltaAg-L to determine whether the monophosphorylation was predominantly at a specific site on the unique 19-amino-acid (aa) extension. We mutated each of the two serines, aa 207 and 210, on this extension and also the serine at aa 177. These three mutations had no significant effect on phosphorylation. In contrast, mutagenesis to alanine of the cysteine at aa 211, which normally acts as the acceptor for farnesylation, completely inhibited phosphorylation. Our interpretation is that the site(s) of phosphorylation is probably not in the 19-aa extension unique to deltaAg-L and that phosphorylation of deltaAg-L may depend upon prior farnesylation. The possible significance of the intracellular phosphorylated forms of deltaAg-L is discussed.